Drug Profile


Alternative Names: AG 337; Nolatrexed dihydrochloride; Orataq; Thymitaq; ZX337

Latest Information Update: 17 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Agouron Pharmaceuticals
  • Developer Agouron Pharmaceuticals; YM BioSciences USA
  • Class Quinazolines; Small molecules
  • Mechanism of Action Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatocellular carcinoma
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Colorectal cancer; Head and neck cancer; Hepatocellular carcinoma; Lung cancer; Pancreatic cancer; Prostate cancer

Most Recent Events

  • 09 May 2006 Eximias Pharmaceutical Corporation has been acquired by YM BioSciences
  • 04 Aug 2005 Eximias presented results showing that the ETHECC trial did not meet its primary endpoint
  • 22 Apr 2005 Eximias has completed enrolment in the ETHECC trial for Hepatocellular carcinoma in Canada, Europe, South Africa and USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top